Alembic Pharma Q4 Profit Rises 25% YoY, Margins Under Pressure

📰 Key Highlights Net Profit: ₹2B vs ₹1.6B YoY → +25% growth Revenue: ₹18.5B vs ₹17.7B YoY → +5% growth EBITDA: ₹2.3B vs ₹2.73B YoY → -16% decline EBITDA Margin: 12.34% vs 15.4% YoY → margin contraction of ~306 bps 🔎 Fundamentals Profit growth supported by higher sales volumes and improved product mix. Margins contracted due to pricing pressure in generics and higher input costs. Revenue growth modest, reflecting competitive global pharma environment. 💊 Business Focus Expanding presence in US generics and specialty formulations. Strengthening domestic branded formulations portfolio. Investing in R&D for oncology and specialty therapies. ⚠️ Risks Regulatory challenges in USFDA approvals. Pricing pressure in generics market. Rising raw material costs impacting margins. 📈 Outlook Strong pipeline in specialty drugs provides growth visibility. Margin recovery will be key for sustained profitability. Alembic Pharma positioning itself as a resilient mid-cap pharma player with global ambitions.